Keywords: ligand, panretin, gel, recommended, approval, fda, advisory
Ligand's Panretin Gel Recommended for Approval by FDA Advisory Committee
Article | 19 November 1998
Ligand Pharmaceuticals says that Panretin gel 0.1% (alitretinoin)has been recommended for approval by the Oncologic Drugs Advisory Committee to the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Is the diabetes market facing a blockbuster-free future?
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
